Zhan Chao Liang
Directeur en chef des Investissements chez Shanghai Med-Fine Asset Management Co. Ltd.
Profil
Zhan Chao Liang is currently the Director at Beijing Mabworks Biotech Co., Ltd.
and the Chief Investment Officer & Partner at Shanghai Med-Fine Asset Management Co. Ltd.
He completed his undergraduate degree from Hlj August First Land Reclamation University in 2008 and his graduate degree from the Academy of Military Medical Sciences in 2011.
Postes actifs de Zhan Chao Liang
| Sociétés | Poste | Début |
|---|---|---|
Beijing Mabworks Biotech Co., Ltd.
 Beijing Mabworks Biotech Co., Ltd. Pharmaceuticals: MajorHealth Technology Beijing Mabworks Biotech Co., Ltd. engages in the discovery, development, manufacturing and commercialization of therapeutic antibodies. It develops antibody drugs and macromolecular biological drugs. The firm’s products include MIL60, MIL62, MIL86, MBS301, MIL77, and MIL93. The company was founded on February 27, 2003 and is headquartered in Beijing, China. | Directeur/Membre du Conseil | 01/05/2016 |
| Shanghai Med-Fine Asset Management Co. Ltd. | Directeur en chef des Investissements | 01/04/2015 |
Formation de Zhan Chao Liang
| Hlj August First Land Reclamation University | Undergraduate Degree |
| Academy of Military Medical Sciences | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 2 |
|---|---|
Beijing Mabworks Biotech Co., Ltd.
Beijing Mabworks Biotech Co., Ltd. Pharmaceuticals: MajorHealth Technology Beijing Mabworks Biotech Co., Ltd. engages in the discovery, development, manufacturing and commercialization of therapeutic antibodies. It develops antibody drugs and macromolecular biological drugs. The firm’s products include MIL60, MIL62, MIL86, MBS301, MIL77, and MIL93. The company was founded on February 27, 2003 and is headquartered in Beijing, China. | Health Technology |
| Shanghai Med-Fine Asset Management Co. Ltd. |